News for Edwards Lifesciences Corporation (E1WL34.SA)

Edwards Lifesciences is projected to deliver steady profit and revenue growth through 2026. Click here to read more on EW stock prospects.

Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial a

We recently published a list of Jim Cramer’s Recent Thoughts on These 15 Stocks. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against other stocks that Jim Cramer discussed recently. On Monday, Mad Money host Jim Cramer addressed the market’s reaction to the recent U.S. debt […]

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against other best medical device stocks to buy now. Trump’s Tariffs Are Dividing the Medical Community On April 16, CNBC reported that Trump’s tariffs […]

Edwards Lifesciences Corporation (EW), a leading medical technology company, has announced the approval of significant amendments to its Employee Stock Purcha

Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovig

Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR)

Edwards Lifesciences (EW) secures FDA approval for its SAPIEN 3 TAVR platform for asymptomatic severe aortic stenosis patients. The approval is based on

We recently published a list of How Did Jim Cramer’s 12 Bold Predictions Play Out?. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against other stocks that Jim Cramer recently discussed. During the most recent episode of Mad Money, Jim Cramer revisited the recent turbulence in […]

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion,

Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA

\nEdwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 202

Edwards Lifesciences Corporation (NYSE: EW) today announced the company's SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter trea

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A copy of the same can be downloaded here. Select Growth primarily targets U.S. companies that are leading the way in crucial areas of positive structural transformation within the economy. The fund returned 8.8% (net) in the fourth […]

PR NewswireGALWAY, Ireland and WASHINGTON, March 9, 2025 CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trial to prim

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025.

Edwards Lifesciences Corporation (NYSE:EW) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ETCompany ParticipantsMark Wilterding - Senior Vice...

Stock Market today | Share Market Live Updates - Find here all the live updates related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 4 February 2025.

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business changes for 2025.